We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “Immunotherapy with checkpoint inhibitors is currently ...

Viruses cannot replicate by themselves. Instead, they rely on the host for almost all their replicative functions. Similarly, many viruses are unable to cause damage without the host immune system.

Researchers have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6). Researchers at The University of Texas ...

In a recent study posted to Research Square*, researchers reported that plasma interleukin (IL)-6 levels in patients with acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 ...

However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease ...

Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine ...

Interleukin-6 (IL-6) is a pleiotropic cytokine that may play a role in the regulation of various aspects of the immune response, inflammation, hematopoiesis, and bone metabolism. IL-6 acts by binding ...

Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial. Epidermal growth factor ...

A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas. This is an ASCO ...